Loading organizations...
§ Private Profile · 9360 Towne Centre Dr. San Diego, CA 92121, USA
Clinical-stage biotech company developing alternative splicing therapeutics for degenerative diseases, oncology.
Biosplice Therapeutics is a clinical-stage biotechnology company based in San Diego, California, that develops small molecule therapeutics targeting alternative pre-mRNA splicing and the Wnt signaling pathway to restore tissue health. The pre-revenue enterprise focuses on treatments for degenerative diseases, oncology, and neurological disorders, with its lead investigational drug candidate, lorecivivint, advancing through Phase 3 clinical trials for knee osteoarthritis. Operating with approximately 200 employees, the firm has secured $799 million in total venture funding across multiple financing rounds and achieved a peak private market valuation of $11.6 billion. The company's capitalization table includes equity investments from prominent institutional backers such as Vickers Venture Partners, Sands Capital Management, aMoon Fund, and IKEA's investment arm. Originally operating under the name Samumed before a corporate rebranding in 2021, the organization was founded in 2008 by Osman Kibar.
Biosplice Therapeutics has raised $558.0M across 2 funding rounds.
Biosplice Therapeutics has raised $558.0M in total across 2 funding rounds.
Biosplice Therapeutics has raised $558.0M across 2 funding rounds. Most recently, it raised $120.0M Other Equity in April 2021.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 15, 2021 | $120M Venture Round | — | JOY Ghosh, Sands Capital, SymBiosis II, Verition Fund Management | Announced |
| Aug 6, 2018 | $438M Series A | — | — | Announced |
Biosplice Therapeutics has raised $558.0M in total across 2 funding rounds.
Biosplice Therapeutics's investors include Joy Ghosh, Sands Capital, SymBiosis II, Verition Fund Management.
Biosplice Therapeutics develops first-in-class small-molecule therapies engineered to precisely modulate alternative pre-mRNA splicing. The company's core approach involves targeting the CLK/DYRK family kinases, which play a critical role in controlling proteome diversification. This foundational technology allows Biosplice to intervene at a fundamental biological level, creating therapeutic candidates designed to correct dysregulated splicing patterns implicated in various human diseases.
The company was founded in 2008 by Osman Kibar. His insight centered on the profound impact of alternative splicing dysregulation as a root cause of numerous debilitating conditions. This understanding propelled the development of a proprietary platform aimed at discovering and advancing novel small molecules that can therapeutically restore healthy splicing, thereby addressing underlying disease mechanisms rather than just symptoms.
Biosplice’s therapeutic candidates are intended for patients facing significant unmet medical needs in areas such as osteoarthritis, oncology, neurology, and diabetes. The company's vision is to advance these targeted therapies through clinical development and ultimately deliver them to patients, with the goal of restoring health and significantly improving patient outcomes across a spectrum of challenging diseases.